Circulating tumour DNA genomics in EGFR-mutant lung adenocarcinoma

[1] Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers [J]. NATURE GENETICS, 2017, 49 (12) : 1693 - +

[2] Concomitant Genetic Alterations With Response to Treatment and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With EGFR-Mutant Advanced Non-Small Cell Lung Cancer [J]. JAMA ONCOLOGY, 2018, 4 (05) : 739 - 742

[3] Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial [J]. JAMA ONCOLOGY, 2015, 1 (02) : 149 - 157

[4] Krail EB, 2017, ELIFE, V6, DOI [10.7554/eLife.18970, 10.7554/eLife.33173]

[5] Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study [J]. LANCET RESPIRATORY MEDICINE, 2018, 6 (02) : 107 - 116

[6] Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions [J]. ANNALS OF ONCOLOGY, 2017, 28 (09) : 2248 - 2255

[7] Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing [J]. NATURE COMMUNICATIONS, 2018, 9

[8] Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer [J]. PLOS MEDICINE, 2006, 3 (10) : 1865 - 1876

[9] Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial [J]. LANCET RESPIRATORY MEDICINE, 2018, 6 (09) : 681 - 690

[1] Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers [J]. NATURE GENETICS, 2017, 49 (12) : 1693 - +

[2] Concomitant Genetic Alterations With Response to Treatment and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With EGFR-Mutant Advanced Non-Small Cell Lung Cancer [J]. JAMA ONCOLOGY, 2018, 4 (05) : 739 - 742

[3] Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial [J]. JAMA ONCOLOGY, 2015, 1 (02) : 149 - 157

[4] Krail EB, 2017, ELIFE, V6, DOI [10.7554/eLife.18970, 10.7554/eLife.33173]

[5] Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study [J]. LANCET RESPIRATORY MEDICINE, 2018, 6 (02) : 107 - 116

[6] Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions [J]. ANNALS OF ONCOLOGY, 2017, 28 (09) : 2248 - 2255

[7] Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing [J]. NATURE COMMUNICATIONS, 2018, 9

[8] Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer [J]. PLOS MEDICINE, 2006, 3 (10) : 1865 - 1876

[9] Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial [J]. LANCET RESPIRATORY MEDICINE, 2018, 6 (09) : 681 - 690